Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ... Primary Author:  Cluzeau T Author(s):  Cluzeau T, McGraw ... has not been investigated. The HepG2 hepatoma cell line was used to investigate in vitro Epo elaboration. Serum collected ...

    Research Article last updated 10/20/2017 - 9:16am.

  2. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... is a single arm pilot study for patients using α/β T cell -depleted PSCT in with alternative donor sources with hematologic ...

    Clinical Trial last updated 06/06/2016 - 3:10pm.

  3. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... is a single arm pilot study for patients using α/β T cell -depleted PSCT in with alternative donor sources with hematologic ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  4. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... time to immune reconstitution (including normalization of T, B and natural killer (NK) cell repertoire and Immunoglobulin G production), and to establish the ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.

  5. T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (MOHEL)

    ... of their disease requires them to receive a stem cell transplant . Stem cells or "mother" cells are the source of ... Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) and the subject's disease is considered ...

    Clinical Trial last updated 04/28/2016 - 12:15pm.

  6. Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

    ... study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of AP1903 ...

    Clinical Trial last updated 06/13/2016 - 1:54pm.

  7. Foundation Update - June 2017

    ... Patients June 29, 2017 Thu 1:00 PM EDT Don't miss these archived webinars! > PNH Non-Transplant ... I had six months to live unless I could find a matching stem cell donor. In Korea, where I’m originally from, much less was known about ...

    Article last updated 10/09/2017 - 2:42pm.

  8. New study hails test to weigh SCT for MDS

    ... Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study Finds ... MDS. In patients 40 years old and over whose MDS didn’t carry TP53 mutations, those with mutations in RAS pathway genes or the JAK2 ...

    Article last updated 02/09/2017 - 9:03am.

  9. Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

    ... lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML. This study will also be ... between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity ...

    Clinical Trial last updated 04/27/2016 - 1:19pm.

  10. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing

    ... Yeung C, Gerds AT, Fang M, Scott BL, Flowers ME, Gooley T, Deeg HJ Original Publication Date:  ... is a major cause of failure after allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndromes ...

    Research Article last updated 06/03/2015 - 12:48pm.